Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"
May 10, 2021
The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.